Directed Shares Decide Day-One IPO Exit or Lock-Up

The trap is simple: you already own pre-IPO equity, so buying more in the offering feels like a way to exit. The rule is that the directed-share paragraph in the underwriting section decides whether that purchase is liquid on day one or locked with the rest of the offering.

Start with the final prospectus, not the press release. The underwriting section is where the underwriters describe how shares will be allocated and what resale restrictions apply. A directed-share program, if one exists, is described there in a short paragraph that can change your liquidity outcome.

The directed-share paragraph is the fastest tell

A directed-share program is an allocation of IPO shares to a selected group, often employees, with terms that may differ from the general offering. The key difference is timing: some programs waive the underwriter lock-up, a resale restriction imposed by the underwriters, for eligible non-directors and non-officers, while others simply give you shares under the same restrictions.

Price action does not answer the question. TRex Bio set the IPO price at $14.00 on October 8, 2026, at the low end of a $14.00 to $16.00 range. The offering included 8,333,334 primary shares at $14 and generated $116.7 million in gross proceeds. On the debut, the stock started at $13.50, hit $15.50 during trading, and finished at $14.00. That tells you how the market reacted in the opening session, not whether an employee's new shares can be sold immediately.

The same section can describe other investors. Eli Lilly preliminarily intended to buy IPO shares so that its post-offering stake would not exceed 19.9%. A separate investor's planned purchase is different from a directed-share program, and it does not tell you whether employees get a waiver.

The three-question check tells you before you size the order

Here is where people go wrong: they see the words directed share and assume the waiver applies to every employee. The waiver can be limited to a named group, and it can still leave officers and directors under the standard underwriter lock-up.

• Ask whether a directed-share program exists. The underwriting section may say the underwriters can allocate a portion of the offering to a directed-share program. Done looks like a named program, a stated allocation, or a clear statement that no such program is being offered.
• Confirm whether you are eligible. Eligibility can be limited by role, plan, or a list maintained by the company or underwriters. You are done when your category appears in the prospectus, or your broker confirms you are on the allocation list before you place the order.
• Check whether the lock-up is waived for non-directors and non-officers. Some programs waive the standard underwriter lock-up for eligible non-directors and non-officers. The check passes when the paragraph says your shares are exempt from the underwriter lock-up or can be sold after the offering without waiting for the standard release.

If all three answers are yes, the purchase can be a day-one exit. If any answer is no, treat the new shares as part of the locked offering and make the decision on that basis.

The same paragraph tests the liquidity outcome

It also tells you what to do with the money you would have raised. If the shares are locked, your liquidity is delayed, so the purchase is less useful for covering taxes, diversifying, or paying down debt. If the shares are exempt, the purchase can function like a partial exit, but only for the amount you can actually sell.

Keep the check tied to the final document. An early prospectus can describe a program that changes before the final terms are set. The version you rely on is the one that matches the final offering terms.

A large recent loss makes the choice harder. TRex Bio had a $46.39 million net loss over the 12 months through June 30, 2026, with no revenue. TRB-061, its lead TNFR2 agonist, was then testing in a Phase 1b study for moderate-to-severe atopic dermatitis, with first results expected by mid-2027. Those numbers do not change the directed-share waiver, but they matter when you decide how much of a potential day-one exit to take.